TY  - GEN
AU  - Martín, Miguel
AU  - Martínez, Noelia
AU  - Ramos, Manuel
AU  - Calvo, Lourdes
AU  - Lluch, Ana
AU  - Zamora, Pilar
AU  - Muñoz, Montserrat
AU  - Carrasco, Eva
AU  - Caballero, Rosalía
AU  - García-Sáenz, José Ángel
AU  - Guerra, Eva
AU  - Caronia, Daniela
AU  - Casado, Antonio
AU  - Ruíz-Borrego, Manuel
AU  - Hernando, Blanca
AU  - Chacón, José Ignacio
AU  - De la Torre-Montero, Julio César
AU  - Jimeno, María Ángeles
AU  - Heras, Lucía
AU  - Alonso, Rosario
AU  - De la Haba, Juan
AU  - Pita, Guillermo
AU  - Constenla, Manuel
AU  - Gonzalez-Neira, Anna
PY  - 2015
DO  - 10.1634/theoncologist.2014-0379
UR  - http://hdl.handle.net/20.500.12105/19852
AB  - BACKGROUNDThe approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint). Dose modifications are often required because of severe hand-foot syndrome (HFS). We tested...
LA  - eng
PB  - Oxford University Press
KW  - Pharmacogenetics
KW  - Adult
KW  - Aged
TI  - Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
TY  - other
ER  -